Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Suzhou Zelgen Biopharmaceuticals Co: Clinical Trials & FDA Approval Profile

Suzhou Zelgen Biopharmaceuticals Co (Global / Institutional) sponsors 56 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 18 active protocols (12 recruiting now), 22 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)8.9%
Median Closed Enrollment vs National (145 pts)123 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Suzhou Zelgen Biopharmaceuticals Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)56
Active Pipeline (Recruiting Now)18 (12)
Completed vs Stopped Early22 / 5 (8.9%)
Median Closed Actual Enrollment123 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Suzhou Zelgen Biopharmaceuticals Co
Hospital Research SiteLocationShared Protocols
Peking Union Medical College HospitalBeijing, Beijing Municipality6
Chinese PLA General HospitalBeijing5
Shanghai Chest HospitalShanghai3

Explore interactive annual charts and M&A subsidiary rollups in the Suzhou Zelgen Biopharmaceuticals Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI